310 related articles for article (PubMed ID: 24952959)
1. Harnessing the anti-inflammatory potential of palmitoylethanolamide.
Alhouayek M; Muccioli GG
Drug Discov Today; 2014 Oct; 19(10):1632-9. PubMed ID: 24952959
[TBL] [Abstract][Full Text] [Related]
2. Adelmidrol increases the endogenous concentrations of palmitoylethanolamide in canine keratinocytes and down-regulates an inflammatory reaction in an in vitro model of contact allergic dermatitis.
Petrosino S; Puigdemont A; Della Valle MF; Fusco M; Verde R; Allarà M; Aveta T; Orlando P; Di Marzo V
Vet J; 2016 Jan; 207():85-91. PubMed ID: 26639824
[TBL] [Abstract][Full Text] [Related]
3. N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis.
Alhouayek M; Bottemanne P; Subramanian KV; Lambert DM; Makriyannis A; Cani PD; Muccioli GG
FASEB J; 2015 Feb; 29(2):650-61. PubMed ID: 25384424
[TBL] [Abstract][Full Text] [Related]
4. N-acylethanolamine-hydrolyzing acid amidase and fatty acid amide hydrolase inhibition differentially affect N-acylethanolamine levels and macrophage activation.
Alhouayek M; Bottemanne P; Makriyannis A; Muccioli GG
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 May; 1862(5):474-484. PubMed ID: 28065729
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of cyanamides as potent and selective N-acylethanolamine acid amidase inhibitors.
Malamas MS; Farah SI; Lamani M; Pelekoudas DN; Perry NT; Rajarshi G; Miyabe CY; Chandrashekhar H; West J; Pavlopoulos S; Makriyannis A
Bioorg Med Chem; 2020 Jan; 28(1):115195. PubMed ID: 31761726
[TBL] [Abstract][Full Text] [Related]
6. Synergic Therapeutic Potential of PEA-Um Treatment and NAAA Enzyme Silencing In the Management of Neuroinflammation.
Casili G; Lanza M; Campolo M; Siracusa R; Paterniti I; Ardizzone A; Scuderi SA; Cuzzocrea S; Esposito E
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050589
[TBL] [Abstract][Full Text] [Related]
7. Anti-Inflammatory Effects of Fucoxanthinol in LPS-Induced RAW264.7 Cells through the NAAA-PEA Pathway.
Jin W; Yang L; Yi Z; Fang H; Chen W; Hong Z; Zhang Y; Zhang G; Li L
Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32326173
[TBL] [Abstract][Full Text] [Related]
8.
Piomelli D; Scalvini L; Fotio Y; Lodola A; Spadoni G; Tarzia G; Mor M
J Med Chem; 2020 Jul; 63(14):7475-7490. PubMed ID: 32191459
[No Abstract] [Full Text] [Related]
9. N-Acylethanolamine acid amidase (NAAA) inhibitor F215 as a novel therapeutic agent for osteoarthritis.
Zhou P; Xiang L; Yang Y; Wu Y; Hu T; Liu X; Lin F; Xiu Y; Wu K; Lu C; Ren J; Qiu Y; Li Y
Pharmacol Res; 2019 Jul; 145():104264. PubMed ID: 31063807
[TBL] [Abstract][Full Text] [Related]
10. The Basal Pharmacology of Palmitoylethanolamide.
Rankin L; Fowler CJ
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114698
[TBL] [Abstract][Full Text] [Related]
11. Advances in the discovery of N-acylethanolamine acid amidase inhibitors.
Bandiera T; Ponzano S; Piomelli D
Pharmacol Res; 2014 Aug; 86():11-7. PubMed ID: 24798679
[TBL] [Abstract][Full Text] [Related]
12. Palmitoylethanolamide (PEA) reduces postoperative adhesions after experimental strabismus surgery in rabbits by suppressing canonical and non-canonical TGFβ signaling through PPARα.
Li Y; Zhao S; Xu S; Li Y; Wang C; Ren J; Li F; Hu X; Lin K; Qiu Y; Xiu Y
Biochem Pharmacol; 2021 Feb; 184():114398. PubMed ID: 33385371
[TBL] [Abstract][Full Text] [Related]
13. Second-Generation Non-Covalent NAAA Inhibitors are Protective in a Model of Multiple Sclerosis.
Migliore M; Pontis S; Fuentes de Arriba AL; Realini N; Torrente E; Armirotti A; Romeo E; Di Martino S; Russo D; Pizzirani D; Summa M; Lanfranco M; Ottonello G; Busquet P; Jung KM; Garcia-Guzman M; Heim R; Scarpelli R; Piomelli D
Angew Chem Int Ed Engl; 2016 Sep; 55(37):11193-11197. PubMed ID: 27404798
[TBL] [Abstract][Full Text] [Related]
14. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation.
Solorzano C; Zhu C; Battista N; Astarita G; Lodola A; Rivara S; Mor M; Russo R; Maccarrone M; Antonietti F; Duranti A; Tontini A; Cuzzocrea S; Tarzia G; Piomelli D
Proc Natl Acad Sci U S A; 2009 Dec; 106(49):20966-71. PubMed ID: 19926854
[TBL] [Abstract][Full Text] [Related]
15. N-acylethanolamine acid amidase (NAAA) inhibition decreases the motivation for alcohol in Marchigian Sardinian alcohol-preferring rats.
Fotio Y; Ciccocioppo R; Piomelli D
Psychopharmacology (Berl); 2021 Jan; 238(1):249-258. PubMed ID: 33037452
[TBL] [Abstract][Full Text] [Related]
16. Palmitoylethanolamide in CNS health and disease.
Mattace Raso G; Russo R; Calignano A; Meli R
Pharmacol Res; 2014 Aug; 86():32-41. PubMed ID: 24844438
[TBL] [Abstract][Full Text] [Related]
17. Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma.
Esposito E; Cuzzocrea S
Mini Rev Med Chem; 2013 Feb; 13(2):237-55. PubMed ID: 22697514
[TBL] [Abstract][Full Text] [Related]
18. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide.
Lo Verme J; Fu J; Astarita G; La Rana G; Russo R; Calignano A; Piomelli D
Mol Pharmacol; 2005 Jan; 67(1):15-9. PubMed ID: 15465922
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase.
Saturnino C; Petrosino S; Ligresti A; Palladino C; De Martino G; Bisogno T; Di Marzo V
Bioorg Med Chem Lett; 2010 Feb; 20(3):1210-3. PubMed ID: 20022504
[TBL] [Abstract][Full Text] [Related]
20. Expression and secretion of N-acylethanolamine-hydrolysing acid amidase in human prostate cancer cells.
Wang J; Zhao LY; Uyama T; Tsuboi K; Wu XX; Kakehi Y; Ueda N
J Biochem; 2008 Nov; 144(5):685-90. PubMed ID: 18806270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
